{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"ADA ever-positive -Avelumab"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"}]}],"title":"ADA ever-positive -PD 0360324"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"ADA ever-positive was defined as at least one positive ADA result at any time point.","groups":[{"description":"During Phase 1b participants received PD 0360324 50 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG000","title":"Combination C Phase 1b: PD 0360324 50 mg + Avelumab"},{"description":"During Phase 1b participants received PD 0360324 100 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG001","title":"Combination C Phase 1b: PD 0360324 100 mg + Avelumab"},{"description":"During Phase 1b participants received PD 0360324 150 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG002","title":"Combination C Phase 1b: PD 0360324 150 mg + Avelumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis population was a subset of the safety analysis set (all participants who received at least one dose of study drug) and included participants who had at least one ADA sample collected for avelumab. Here, \"Number of participants analyzed'' signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 1 of Cycle 1, 2, 4, 6, and 10","title":"Number of Participants With Positive ADA Levels For Combination C","type":"SECONDARY","unitOfMeasure":"Participants"}